论文部分内容阅读
目的探讨PDCD5基因多态性与乳腺癌患者临床病理特征及预后的关系。方法采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析方法,检测311例长期随访的原发性乳腺癌患者PDCD5基因多态性,用Pearsonχ2检验分析PDCD5基因多态性与乳腺癌患者临床病理特征间的关系,并通过Kaplan-Meier曲线分析其与乳腺癌患者生存率之间的关系。结果在311例乳腺癌病例中,PDCD5 CG/GG基因携带者的孕激素受体(progesterone receptor,PR)阴性率(50.9%)显著高于CC基因携带者的PR阴性率(38.6%),P=0.035;PDCD5基因多态与乳腺癌患者的其他临床病理特征均无相关性(P>0.05),也未见其与患者预后相关(P>0.05)。结论PR阴性高表达的乳腺癌患者常提示预后不良。PDCD5基因多态与PR阴性高表达有关,提示PDCD5基因型可能与预后不良有关,但生存分析却未显现其与乳腺癌患者预后间具有相关性。本研究结果初步显示,PDCD5基因多态性检测对女性乳腺癌患者预后评价可能没有直接参考价值。
Objective To investigate the relationship between PDCD5 gene polymorphism and clinicopathological features and prognosis in patients with breast cancer. Methods Polymorphisms of PDCD5 gene in 311 patients with long-term follow-up of primary breast cancer were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Pearsonχ2 test was used to analyze the association between PDCD5 gene polymorphism and Breast cancer patients with clinicopathological features and Kaplan-Meier curve analysis of its relationship with the survival rate of breast cancer patients. Results In 311 cases of breast cancer, the positive rate of progesterone receptor (PR) in PDCD5 CG / GG gene carriers was significantly higher than that in CC carriers (50.9% vs 38.6%, P = 0.035. There was no correlation between PDCD5 gene polymorphism and other clinicopathological features (P> 0.05), and no correlation between PDCD5 gene polymorphism and prognosis (P> 0.05). Conclusion PR-negative breast cancer patients often indicate poor prognosis. PDCD5 gene polymorphism and PR negative high expression, suggesting that PDCD5 genotype may be related to poor prognosis, but the survival analysis did not show its correlation with the prognosis of breast cancer patients. The preliminary results of this study show that PDCD5 gene polymorphism detection may have no direct reference value for the prognosis of female breast cancer patients.